The Asia Pacific Sickle Cell Disease Treatment Market would witness market growth of 28.8% CAGR during the forecast period (2023-2030).
Growth of the market is also anticipated to be fuelled by the increasing approval of novel therapeutic medications for treating the condition. Additionally, rising government involvement in enhancing healthcare services and disease awareness is anticipated to fuel market expansion. The inaccessibility of medications in rural areas will present further possibilities for expanding the market in the coming years. Additionally, many hospitals and international organizations have also initiated several campaigns to raise awareness about hemoglobin deficiency.
The sickle cell disease pipeline consists of large pharmaceutical corporations with novel drugs in clinical trials and mid-sized and minor pharmaceutical companies with early-stage pipeline products. Due to the high efficacy of these treatments in early clinical studies, regulatory agencies have a favourable opinion of them, thereby aiding the rapid development of these medications by their vendors. Recent technological developments and the identification of sickle cell disease also fuel the strong pipeline for treating sickle cell disorders.
According to the International Trade Administration, China's healthcare sector grew strongly in 2018 and experienced dynamic regulatory change. China's demand for medical devices reached USD 78.81 billion. In 2018, sales of pharmaceutical and health products totalled USD 219.91 billion. The demand for medical devices has maintained a double-digit increase for over a decade, making it one of China's fastest-growing product sectors. Over 70% of this rise was attributed to hospital procurement. Access to improved medical facilities and specialized care has improved the diagnosis and treatment of SCD in the Asia-Pacific region.
The China market dominated the Asia Pacific Sickle Cell Disease Treatment Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $547.4 Million by 2030. The Japan market is registering a CAGR of 28% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 29.6% during (2023 - 2030).
Based on Treatment, the market is segmented into Blood Transfusion, Pharmacotherapy, and Bone Marrow Transplant. Based on End-Use, the market is segmented into Hospitals, Specialty Clinics and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Sickle Cell Disease Treatment Market is Projected to reach USD 7.3 Billion by 2030, at a CAGR of 27.9%
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Novartis AG, Pfizer Inc., bluebird bio, Inc., CSL Limited, Emmaus Life Sciences, Inc., Bristol Myers Squibb Company, CRISPR Therapeutics AG, Agios Pharmaceuticals, Inc. (LES LABORATOIRES SERVIER SAS), Novo Nordisk A/S and Medunik USA (Duchesnay Inc.).
By Treatment
By End-Use
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
